A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects with Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)

Phase: Phase 3 - Active, Not Recruiting

Condition(s): Limb Girdle Muscular Dystrophy 2E/R4

Keyword(s): 2022-503112-17-00 ( Other Identifier ) (OTHER: Clinical Trials Information System (CTIS)

NCT Number: NCT06246513 Other Study ID Number(s): SRP-9003-301

Study Overview

This is a multicenter, global study of the effects of a single systemic dose of SRP-9003 on beta-sarcoglycan (β-SG) gene expression in participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4).

Participation Criteria

  • Cohort 1, only ambulatory participants:
    • Able to walk without assistive aid
    • 10-meter walk test (10MWT) <30 seconds
    • NSAD ≥25
  • Cohort 2, only non-ambulatory participants:
    • 10MWT ≥30 seconds or unable to perform
    • PUL 2.0 entry scale score ≥3
  • Aged 4 years and older
  • Participants must possess 1 homozygous or 2 heterozygous pathogenic and/or likely pathogenic β-SG DNA gene mutations
  • Able to cooperate with muscle testing
  • Participants must have adeno-associated virus serotype rh74 (AAVrh74) antibody titers <1:400 (that is, not elevated) as determined by AAVrh74 antibody enzyme-linked immunosorbent assay.

Study Plan

Participants will receive a single intravenous (IV) infusion of SRP-9003. The participants will be monitored for 5 years after the infusion. 

Principal Investigator

Anne M. Connolly
MD

Neurology